New ways to diagnose lymphoma and castleman disease
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests new methods to diagnose lymphoma and multicentric castleman disease, which are conditions that can affect people with HIV. It may help find these diseases earlier and more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old and weigh at least 10 kilograms (about 22 pounds).
- You must be infected with HIV.
- You must have at least one swollen lymph node that is 2 centimeters (about 0.8 inches) or larger and can be biopsied.
- You (or your guardian) must agree to participate and sign a consent form.
- You must not have had cancer in the last 5 years, except for Kaposi sarcoma, which is allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
This study uses a small tissue sample from an often-accessible lymph node to learn how HIV affects the body. It may help researchers understand why some people control HIV better than others.
This study follows people with Kaposi sarcoma to learn more about the disease and how it changes over time. It may help doctors better understand and treat KS in the future.
This study tests a drug called pacritinib for people with KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS). It aims to see if the drug can help control symptoms and inflammation caused by these conditions.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study measures how much HIV is in your blood and lymph node tissue. If you qualify, you would also allow blood and other tests (including genetic and hepatitis screening), which may help researchers better understand how HIV affects the body.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.